Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates methamphetamine-induced sensitization in mice

European Journal of Neuroscience

Volumn 33, Issue 7, 2011, Pages 1197-1204

  Motawaj, Mouhammad ^a   Arrang, Jean Michel ^a  

^a CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

Author keywords

Behavioural sensitization; Histamine neurons; Psychostimulants; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CIPROXIFAN; IMETIT; MESSENGER RNA; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1;

AGED; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; HIPPOCAMPUS; HYPOTHALAMUS; LOCOMOTION; MALE; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CENTRAL NERVOUS SYSTEM STIMULANTS; HISTAMINE AGONISTS; HISTAMINE H3 ANTAGONISTS; HUMANS; IMIDAZOLES; MALE; METHAMPHETAMINE; MICE; MOTOR ACTIVITY; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; THIOUREA;

EID: 79953285652     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2011.07618.x     Document Type: Article

References (58)

1. Jr & Jones, E.G. (1996) Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J. Neurosci., 16, 19-30.
2. Arrang, J.M. (2007) Histamine and schizophrenia. Int. Rev. Neurobiol., 78, 247-287.
3. 3-receptors. Nature, 327, 117-123.
4. Banerjee, P.S., Aston, J., Khundakar, A.A. & Zetterstrom, T.S. (2009) Differential regulation of psychostimulant-induced gene expression of brain derived neurotrophic factor and the immediate-early gene Arc in the juvenile and adult brain. Eur. J. Neurosci., 29, 465-476.
5. Belforte, J.E., Zsiros, V., Sklar, E.R., Jiang, Z., Yu, G., Li, Y., Quinlan, E.M. & Nakazawa, K. (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat. Neurosci., 13, 76-83.
6. Berton, O., McClung, C.A., Dileone, R.J., Krishnan, V., Renthal, W., Russo, S.J., Graham, D., Tsankova, N.M., Bolanos, C.A., Rios, M., Monteggia, L.M., Self, D.W. & Nestler, E.J. (2006) Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science, 311, 864-868.
7. 3-receptor inverse agonists. Psychopharmacology (Berl), 210, 591-604.
8. Caldeira, M.V., Melo, C.V., Pereira, D.B., Carvalho, R.F., Carvalho, A.L. & Duarte, C.B. (2007) BDNF regulates the expression and traffic of NMDA receptors in cultured hippocampal neurons. Mol. Cell. Neurosci., 35, 208-219.
9. 3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. Eur. J. Pharmacol., 259, 107-114.
10. 3 receptors. J. Pharmacol. Exp. Ther., 326, 406-413.
11. El-Ghundi, M.B., Fan, T., Karasinska, J.M., Yeung, J., Zhou, M., O'Dowd, B.F. & George, S.R. (2010) Restoration of amphetamine-induced locomotor sensitization in dopamine D1 receptor-deficient mice. Psychopharmacology (Berl), 207, 599-618.
12. Faucard, R., Armand, V., Heron, A., Cochois, V., Schwartz, J.C. & Arrang, J.M. (2006) N-methyl-D-aspartate receptor antagonists enhance histamine neuron activity in rodent brain. J. Neurochem., 98, 1487-1496.
13. 2 receptors and the implications for striatal function. Neuropharmacology, 55, 190-197.
14. Fox, G.B., Esbenshade, T.A., Pan, J.B., Radek, R.J., Krueger, K.M., Yao, B.B., Browman, K.E., Buckley, M.J., Ballard, M.E., Komater, V.A., Miner, H., Zhang, M., Faghih, R., Rueter, L.E., Bitner, R.S., Drescher, K.U., Wetter, J., Marsh, K., Lemaire, M., Porsolt, R.D., Bennani, Y.L., Sullivan, J.P., Cowart, M.D., Decker, M.W. & Hancock, A.A. (2005) Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J. Pharmacol. Exp. Ther., 313, 176-190.
15. Gao, X.M., Sakai, K., Roberts, R.C., Conley, R.R., Dean, B. & Tamminga, C.A. (2000) Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am. J. Psychiatry, 157, 1141-1149.
16. 3 receptor agonist. J. Pharmacol. Exp. Ther., 263, 304-310.
17. Guillin, O., Griffon, N., Diaz, J., Le Foll, B., Bezard, E., Gross, C., Lammers, C., Stark, H., Carroll, P., Schwartz, J.C. & Sokoloff, P. (2004) Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway. Int. Rev. Neurobiol., 59, 425-444.
18. Haas, H.L., Sergeeva, O.A. & Selbach, O. (2008) Histamine in the nervous system. Physiol. Rev., 88, 1183-1241.
19. 3 receptor antagonists/inverse agonists as anti-obesity agents. Curr. Opin. Investig. Drugs, 4, 1190-1197.
20. 3 receptor ligands and neurological disease. Expert Opin. Investig. Drugs, 13, 1237-1248.
21. Hill, S.J., Ganellin, C.R., Timmerman, H., Schwartz, J.C., Shankley, N.P., Young, J.M., Schunack, W., Levi, R. & Haas, H.L. (1997) International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol. Rev., 49, 253-278.
22. 35S]GTPgamma[S] binding in rat striatum: evidence for additive effects but lack of interactions. Biochem. Pharmacol., 73, 1172-1181.
23. Ibrahim, H.M., Hogg, A.J. Jr, Healy, D.J., Haroutunian, V., Davis, K.L. & Meador-Woodruff, J.H. (2000) Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am. J. Psychiatry, 157, 1811-1823.
24. 3-receptor antagonist, in a light/dark test measuring anxiety in mice. Life Sci., 53, 1675-1683.
25. Ito, C., Onodera, K., Sakurai, E., Sato, M. & Watanabe, T. (1996) Effects of dopamine antagonists on neuronal histamine release in the striatum of rats subjected to acute and chronic treatments with methamphetamine. J. Pharmacol. Exp. Ther., 279, 271-276.
26. Kalivas, P.W. & Stewart, J. (1991) Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Brain Res. Rev., 16, 223-244.
27. Kalivas, P.W., Lalumiere, R.T., Knackstedt, L. & Shen, H. (2009) Glutamate transmission in addiction. Neuropharmacology, 56(Suppl 1), 169-173.
28. 2 receptor knockout mice. Genes Brain Behav., 7, 568-577.
29. 3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology (Berl), 167, 363-372.
30. Law, A.J. & Deakin, J.F. (2001) Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport, 12, 2971-2974.
31. 3-receptor antagonist. J. Pharmacol. Exp. Ther., 287, 658-666.
32. 3 receptor: preclinical pharmacology. J. Pharmacol. Exp. Ther., 320, 365-375.
33. Lin, J.S. (2000) Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med. Rev., 4, 471-503.
34. Meador-Woodruff, J.H. & Healy, D.J. (2000) Glutamate receptor expression in schizophrenic brain. Brain Res. Brain Res. Rev., 31, 288-294.
35. Mohn, A.R., Gainetdinov, R.R., Caron, M.G. & Koller, B.H. (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell, 98, 427-436.
36. 3-receptor activation inhibits dopamine synthesis in rat striatum. Neuroreport, 11, 163-166.
37. Monteggia, L.M., Barrot, M., Powell, C.M., Berton, O., Galanis, V., Gemelli, T., Meuth, S., Nagy, A., Greene, R.W. & Nestler, E.J. (2004) Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc. Natl. Acad. Sci. USA, 101, 10827-10832.
38. 3 receptors regulates histamine neurons in brain. Nature, 408, 860-864.
39. 3 receptor. J. Pharmacol. Exp. Ther., 300, 621-628.
40. Nestler, E.J. (2001) Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci., 2, 119-128.
41. Pan, J.B., Yao, B.B., Miller, T.R., Kroeger, P.E., Bennani, Y.L., Komater, V.A., Esbenshade, T.A., Hancock, A.A., Decker, M.W. & Fox, G.B. (2006) Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121. Life Sci., 79, 1366-1379.
42. 3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem. Pharmacol., 73, 1157-1171.
43. Pierce, R.C. & Kalivas, P.W. (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res. Brain Res. Rev., 25, 192-216.
44. 3 receptor and its gene transcripts in rat brain. Neuroscience, 114, 173-193.
45. 3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. J. Neurosci., 22, 7272-7280.
46. 3-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum. Eur. J. Neurosci., 17, 307-314.
47. Prast, H., Heistracher, M. & Philippu, A. (1993) Modulation by dopamine receptors of the histamine release in the rat hypothalamus. Naunyn Schmiedebergs Arch. Pharmacol., 347, 301-305.
48. Prell, G.D., Green, J.P., Kaufmann, C.A., Khandelwal, J.K., Morrishow, A.M., Kirch, D.G., Linnoila, M. & Wyatt, R.J. (1995) Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr. Res., 14, 93-104.
49. 3-receptors following destruction of the ascending dopaminergic neurones. Br. J. Pharmacol., 118, 585-592.
50. 1 receptor-induced cAMP accumulation in rat striatal slices. Neurosci. Lett., 364, 179-184.
51. 3 receptors. J. Neural Transm. Gen. Sect., 93, 1-10.
52. 3 receptor antagonist GSK207040. Psychopharmacology (Berl), 201, 483-494.
53. Svensson, A., Carlsson, M.L. & Carlsson, A. (1995) Crucial role of the accumbens nucleus in the neurotransmitter interactions regulating motor control in mice. J. Neural Transm. Gen. Sect., 101, 127-148.
54. Takino, N., Sakurai, E., Kuramasu, A., Okamura, N. & Yanai, K. (2009) Roles of the histaminergic neurotransmission on methamphetamine-induced locomotor sensitization and reward: a study of receptors gene knockout mice. Int. Rev. Neurobiol., 85, 109-116.
55. Vanderschuren, L.J. & Kalivas, P.W. (2000) Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl), 151, 99-120.
56. Yao, W.D., Gainetdinov, R.R., Arbuckle, M.I., Sotnikova, T.D., Cyr, M., Beaulieu, J.M., Torres, G.E., Grant, S.G. & Caron, M.G. (2004) Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron, 41, 625-638.
57. Zakharenko, S.S., Patterson, S.L., Dragatsis, I., Zeitlin, S.O., Siegelbaum, S.A., Kandel, E.R. & Morozov, A. (2003) Presynaptic BDNF required for a presynaptic but not postsynaptic component of LTP at hippocampal CA1-CA3 synapses. Neuron, 39, 975-990.
58. 3 receptor antagonists and antipsychotic drugs. Brain Res., 1045, 142-149.